Home > Drugs A – Z > Bexarotene (By mouth)

Bexarotene (By mouth)

Treats skin problems. This medicine is a retinoid.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Bexarotene belongs to the group of medicines known as retinoids. It is used to treat a certain type of cancer called cutaneous T-cell lymphoma. It works by interfering with the growth of the cancerous cells. This medicine is available only with your doctor's prescription… Read more
Brand names include
Targretin
Other forms
On the skin
Drug classes About this
Antineoplastic Agent

What works? Research summarized

Evidence reviews

Treatments for mycosis fungoides (a malignant condition with blood cells initially affecting the skin)

Mycosis fungoides is a chronic, malignant disease causing blood cells responsible for the human immune system to affect the skin. People of all ages and from all ethnic backgrounds can develop this disease. Mycosis fungoides can cause physical symptoms that typically occur in a certain sequence making it possible to classify the disease in different stages. Usually this disease starts with patches on the body and extremities. After some time (often years), these patches develop into plaques, and further progress into solid tumours is possible. Lymph nodes and other organs can also be affected, but progress of the disease in most cases is slow compared to other malignant diseases. Life expectancy in the first stage of the disease is similar to people without mycosis fungoides; whereas, prognosis in the later stages of the disease gets worse.

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness [Internet]

Lung cancer is the leading cause of cancer death in both men and women in the United States, and male Veterans seeking care at VA hospitals have a much higher age-specific incidence of lung cancer than males in the general population. The personal and economic significance of lung cancer has led to a vast research endeavor to try and identify new and more effective treatments. Most patients with lung cancer are diagnosed when the cancer is already advanced (stage IIIB or IV), and they are no longer candidates for surgical resection. Small cell lung cancer and non-small cell lung cancer (NSCLC) are different diseases in terms of treatment. Until recently, all therapies for advanced NSCLC were based on their cytotoxic properties. In the last few years, several novel agents aimed at specific molecular targets have been developed. This review was requested to evaluate the current evidence on the effectiveness and cost-effectiveness of treatments for advanced lung cancer.

Systematic review of combination therapies for mycosis fungoides

BACKGROUND: A variety of therapeutic options are available for mycosis fungoides, the most prevalent subtype of cutaneous T cell lymphomas, but thus far, no regimen has been proven to be curative. A combination of treatments is a well-established strategy to increase the therapeutic efficacy. However, data from clinical trials analyzing such combinations for the treatment of mycosis fungoides are scarce.

Summaries for consumers

Nutrition in Cancer Care (PDQ®): Patient Version

Expert-reviewed information summary about the causes and management of nutritional problems that occur in patients with cancer.

Treatments for mycosis fungoides (a malignant condition with blood cells initially affecting the skin)

Mycosis fungoides is a chronic, malignant disease causing blood cells responsible for the human immune system to affect the skin. People of all ages and from all ethnic backgrounds can develop this disease. Mycosis fungoides can cause physical symptoms that typically occur in a certain sequence making it possible to classify the disease in different stages. Usually this disease starts with patches on the body and extremities. After some time (often years), these patches develop into plaques, and further progress into solid tumours is possible. Lymph nodes and other organs can also be affected, but progress of the disease in most cases is slow compared to other malignant diseases. Life expectancy in the first stage of the disease is similar to people without mycosis fungoides; whereas, prognosis in the later stages of the disease gets worse.

Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of mycosis fungoides and the Sézary syndrome.

See all (4)

PubMed Health Blog...

read all...